Aquestive Therapeutics (NASDAQ:AQST) had its price target lowered by BMO Capital Markets to $21.00 in a research report issued on Friday, The Fly reports. The brokerage presently has an “outperform” rating on the stock. BMO Capital Markets’ price target indicates a potential upside of 229.67% from the company’s current price.
A number of other equities research analysts have also issued reports on AQST. Zacks Investment Research lowered shares of Aquestive Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, November 20th. Wedbush upped their price objective on shares of Aquestive Therapeutics from $29.00 to $30.00 and gave the company an “outperform” rating in a report on Thursday, December 6th. Finally, Lake Street Capital initiated coverage on shares of Aquestive Therapeutics in a report on Thursday, January 3rd. They issued a “buy” rating and a $14.00 price objective for the company. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $23.60.
Shares of AQST opened at $6.37 on Friday. The company has a quick ratio of 3.42, a current ratio of 3.63 and a debt-to-equity ratio of 1.88. Aquestive Therapeutics has a 12-month low of $5.60 and a 12-month high of $20.70.
Aquestive Therapeutics (NASDAQ:AQST) last announced its quarterly earnings data on Thursday, March 14th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.91) by $0.35. On average, research analysts anticipate that Aquestive Therapeutics will post -1.15 EPS for the current fiscal year.
A number of hedge funds have recently made changes to their positions in AQST. New York State Common Retirement Fund purchased a new position in Aquestive Therapeutics during the fourth quarter worth about $28,000. Bank of New York Mellon Corp purchased a new position in Aquestive Therapeutics during the fourth quarter worth about $108,000. Millennium Management LLC purchased a new position in Aquestive Therapeutics during the fourth quarter worth about $145,000. Squarepoint Ops LLC purchased a new position in Aquestive Therapeutics during the fourth quarter worth about $188,000. Finally, Keybank National Association OH purchased a new position in Aquestive Therapeutics during the third quarter worth about $239,000. 58.34% of the stock is owned by institutional investors.
About Aquestive Therapeutics
Aquestive Therapeutics, Inc, a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. Its products are developed using its PharmFilm technology. The company's marketed products include Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron antagonist for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery.
Recommended Story: What is Put Option Volume?
Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.